載入...
Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type()
The COVID-19 pandemic in the United States created a unique situation where multiple molecular SARS-CoV-2 diagnostic assays rapidly received Emergency Use Authorization by the FDA and were validated by laboratories and utilized clinically, all within a period of a few weeks. We compared the performa...
Na minha lista:
| 發表在: | Diagn Microbiol Infect Dis |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Elsevier Inc.
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7470790/ https://ncbi.nlm.nih.gov/pubmed/32980807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.diagmicrobio.2020.115200 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|